1-2 of 2
Kristen Lantz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Free
María-Victoria Mateos, Nizar Bahlis, Aurore Perrot, Ajay Nooka, Jin Lu, Charlotte Pawlyn, Roberto Mina, Gaston Caeiro, Alain Kentos, Vania Hungria, Donna Reece, Ting Niu, Anne Mylin, Charlotte Hansen, Raphael Teipel, Britta Besemer, Meletios Dimopoulos, Elena Zamagni, Satoshi Yoshihara, Kihyun Kim, Chang-Ki Min, Paulus Geerts, Elena Van Leeuwen-Segarceanu, Agata Tyczynska, Juan Luis Reguera, Magnus Johansson, Markus Hansson, Mehmet Turgut, Mark Grey, Surbhi Sidana, Paula Rodriguez-Otero, Joaquin Martinez-Lopez, Hamza Hashmi, Robin Carson, Rachel Kobos, Weili Sun, Kristen Lantz, Anne Seifert, Debbie Briseno-Toomey, Lisa O'Rourke, Maria Rubin, Diego Vieyra, Lijuan Kang, Luciano Costa
Journal: Blood
Blood (2025) 146 (Supplement 2): LBA-6.
https://doi.org/10.1182/blood-2025-LBA-6
Published: 2025
Journal Articles

Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis

Free
Xiaoyu Yan, Pamela L Clemens, Thomas Puchalski, Sagar Lonial, MD, Henk M. Lokhorst, Robert Z. Orlowski, MD PhD, Nedjad Losic, Imran Khan, Richard Jansson, Tahamtan Ahmadi, Kristen Lantz, Juan Jose Perez Ruixo, Honghui Zhou, Xu Steven Xu
Journal: Blood
Blood (2015) 126 (23): 4222.
https://doi.org/10.1182/blood.V126.23.4222.4222
Published: 2015